Compare Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF vs Tempus AI — how do they compare? Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.55 (market cap $7.77B), while Tempus AI trades at $70.3 (market cap $12.58B). The key difference: Tempus AI is the larger of the two by market cap, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days and Tempus AI for 22 Days on average.
| PDBC | TEM | |
|---|---|---|
Market Cap | $7.77B | $12.58B |
Volume | 6,100,303 | 7,444,569 |
52-Week High | $20.10 | $99.28 |
52-Week Low | $13.16 | $41.55 |
Typical Hold Time | 56 Days | 22 Days |
Sector | — | Broad Market / Factor |
Enterprise Value | — | $13.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PDBC, the Invesco Optimum Yield Diversified Commodity Strategy ETF, trades at $19.41 with a slight 0.26% decline. Technical indicators show a neutral overall signal with bullish moving averages. The ETF has demonstrated strong performance with 45.66% year-to-date gains through Q3 2026, driven by energy and agricultural commodities amid geopolitical tensions. Recent institutional activity shows mixed signals with significant short interest growth alongside new institutional investments.
The outlook for PDBC remains tied to commodity market dynamics, with potential upside from continued geopolitical tensions and defensive portfolio shifts. However, risks include the 215% surge in short interest and commodity price volatility. The ETF offers exposure to broad commodities diversification but faces headwinds from potential market normalization.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.
The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
